(Q44394691)

English

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects

scientific article published on 19 November 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

author name string

Thomas N Kakuda

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Rodica M Van Solingen-Ristea

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Joelle Onkelinx

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Tanja Stevens

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Fatima Aharchi

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Goedele De Smedt

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Monika Peeters

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Lorant Leopold

8

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Richard M W Hoetelmans

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

19 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

422-431

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of etravirine

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Interaction potential of etravirine with drug transporters assessed in vitro

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetic interactions between etravirine and non-antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.214

21 January 2018

Identifiers

10.1002/JCPH.214

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44394691&oldid=2020957026"